Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 51
Stable insulin leadership position in Region AAMEO
comprising Africa, Asia, Middle-East and Oceania
Region AAMEO insulin market by segment
Region AAMEO modern and new-generation
tMU
120
100
80
60
40
20
0
May
2013
-
CAGR value¹:
Device penetration
CAGR volume¹: 7.7%
4.2%
—
MI and NGI penetration
Penetration
Novo Nordisk
Sanofi
insulin volume market shares
Eli Lilly
100%
70%
60%
80%
Fast-acting
50%
60%
40%
Premix
30%
40%
20%
20%
Long-acting
10%
0%
0%
May
2018
May
2013
Biocon
56%
20%
14%
3%
May
2018
1 CAGR for 5-year period.
Note: IQVIA only covers the following 8 markets in AAMEO (retail data): Algeria, Egypt, India, New
Zealand, Russia, Saudi Arabia, South Africa & Turkey, which together account for 82% of Novo Nordisk
insulin sales in AAMEO
Source: IQVIA monthly MAT May, 2018 volume and value (DKK) figures
MI: Modern insulin; NGI: New-generation insulin
Source: IQVIA monthly MAT May, 2018 volume figures, numbers do not add up to 100% due to smaller
insulin manufacturers
novo nordiskView entire presentation